As much as I'm not thrilled with the market reaction there is nothing yet to show sales are any worse than current guidance. Also, Acadia is clearly putting big efforts behind growing Daybue sales and the obvious upside is the increased spending to achieve that won't cost Neuren anything. I think the persistence was encouraging and it's a lot about penetrating further outside the Centres of Excellence. COA covered this in the questions and mentioned there was a plateau in new patient starts so the share price reaction is likely coming off that. They want more people to directly engage and inform new patients to deal with the GI issues. This will take time and money but not Neuren's money.
NEU Price at posting:
$11.00 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)